Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Abstract Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is the prolonged suppression of testosterone levels af...

Full description

Bibliographic Details
Main Authors: Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susane Krege, Jürgen Gschwend, Heidrun Rexer, Michael Stöckle
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Trials
Subjects:
Castration-resistant prostate cancer
LHRH therapy
Abiraterone
Testosterone
Luteinizing hormone
Online Access:http://link.springer.com/article/10.1186/s13063-017-2195-x

Internet

http://link.springer.com/article/10.1186/s13063-017-2195-x

Similar Items